JCEM: Predictive factor for the condition of patients with hypertrophic limb hypertrophics after butterfly bone surgery

Butterfly bone surgery (TSS) is the preferred treatment for patients with hypertrophic limbs.
is especially important to identify patients who cannot be surgically cured at an early stage, neither to inform patients of expected outcomes or to select patients who may require additional treatment.
recently, a study published in Journal of Clinical Endocrinology and Metabolism, an authoritative journal in the field of endocrine and metabolic diseases, aims to identify predictive factors for the remission of the condition after receiving TSS in patients with hypertrophic conditions.
a multi-center study with retrospective data collected by researchers from three third-level neurosurgery referral centers in the Netherlands.
researchers analyzed clinical data from three queues since 2000 (Groningen, Nemegen and Rotterdam, for a total of n-282).
Based on the 2010 consensus criteria, the researchers used multiple regression models to determine predictors of early biochemic indicator mitigation (12 weeks to 1 year after surgery), long-term remission, and relative decreases in insulin-like growth factors-1 (IGF-1) and growth hormone (GH).
largest tumor diameter (OR 0.91, 95% CI 0.87-0.96, p≤0.0001) was associated with a lower risk of early bio-chemical index mitigation.
largest tumor diameter (OR 0.93, 95% CI 0.89-0.97, p-0.0022) and higher randomly measured GH concentration (OR 0.98, 95% CI 0.96-0.99, p-0.0053) were associated with a lower tumor occurrence rate.
, it can be seen that the maximum tumor diameter and randomly measured GH concentration are the best predictive indicators of disease relief after TSS in patients with hypertrophic limb hypertrophic disease.